Literature DB >> 15115451

Angiotensin-converting enzyme inhibitors (ACEIs) and age-related maculopathy (ARM): cross-sectional findings from the Blue Mountains Eye Study.

Kathy H C Wu1, Jie Jin Wang, Elena Rochtchina, Suriya Foran, Martin K C Ng, Paul Mitchell.   

Abstract

PURPOSE: To assess the relationship between the use of angiotensin-converting enzyme inhibitors (ACEIs) and prevalence of age-related maculopathy (ARM).
METHODS: Eligible residents aged >/= 49 years were first examined in 1992-94 (Cross-section 1, n = 3654). Of these, 2335 were re-examined in 1997-99, together with an additional 1174 who became eligible after 1994 (Cross-section 2, n = 3509). Information regarding ACEI use was obtained and retinal photographs were graded using the Wisconsin ARM Grading System.
RESULTS: In Cross-section 1, prevalence rates of late and early stage ARM were 1.3% and 4.3% among current ACEI users, and 2.0% and 4.8% among non-current users, respectively. In Cross-section 2, prevalence rates of late and early stage ARM were 2.3% and 11.3% among current ACEI users, and 1.3% and 9.3% among non-current users, respectively. After adjusting for age, sex and smoking, neither survey found any significant association between ACEI use and prevalence of either late or early ARM.
CONCLUSIONS: No significant cross-sectional associations were found between ACEI use and ARM prevalence in this population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115451     DOI: 10.1111/j.1600-0420.2004.00265.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  2 in total

1.  Renin-Angiotensin System Inhibitor Usage and Age-Related Macular Degeneration among Hypertensive Patients: Results from the National Health and Nutrition Examination Survey, 2005-2008.

Authors:  Chi Ren; Weiming Liu; Xue Yin; Bingyu Zhang; Peirong Lu
Journal:  J Ophthalmol       Date:  2020-06-24       Impact factor: 1.909

2.  Angiotensin-converting enzyme inhibitors and risk of age-related macular degeneration in individuals with hypertension.

Authors:  Anuradhaa Subramanian; Diana Han; Tasanee Braithwaite; Rasiah Thayakaran; Dawit T Zemedikun; Krishna M Gokhale; Wen Hwa Lee; Jesse Coker; Pearse A Keane; Alastair K Denniston; Krishnarajah Nirantharakumar; Laurent Azoulay; Nicola J Adderley
Journal:  Br J Clin Pharmacol       Date:  2022-05-11       Impact factor: 3.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.